Northwell Cancer Institute Appoints Dr Douglas Gladstone Chief of Hematologic Malignancies

Northwell Health announced today it has appointed Dr Douglas Gladstone a leader in hematology and medical oncology, as chief of hematologic malignancies at the Northwell Health Cancer Institute.

Prior to joining Northwell, Dr. Gladstone served for 14 years as clinical director of the outpatient bone marrow transplantation program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, MD.

In his new role, Dr. Gladstone will work with physician leaders in leukemia, lymphoma, multiple myeloma, bone marrow transplant and classic hematology to enhance clinical and research programs.

“We are thrilled Dr. Gladstone has joined Northwell’s Cancer Institute to lead the division of hematologic malignancies across our health system in the New York metropolitan region,” said Richard Barakat, MD, physician-in-chief and director of the Northwell Health Cancer Institute, and senior vice president of cancer services at Northwell Health. “His more than two decades of clinical expertise, cutting-edge research and academic teaching in the field of blood cancers and benign blood disorders will be a tremendous asset at the Cancer Institute as we advance programs and drive innovative approaches for cancer treatments.”

At the Cancer Institute, Dr. Gladstone will help establish an outpatient hematopoietic and cellular transplant center at Northwell, broaden the use of CAR T-cell therapy, and explore the role of transplanting regulatory T cells, which modulate our immune response and have the potential to treat chronic inflammatory diseases and severe infections such as COVID-19.

“Among my key goals will be to collaborate with my colleagues to unify hematology care across the health system as well as help lead efforts for the Northwell Cancer Institute to earn National Cancer Institute (NCI)-designation, which recognizes cancer centers for their scientific leadership in laboratory and clinical research, as well as serving their communities and promoting and training a range of healthcare professionals”

Dr. Gladstone received his medical degree at the NYU Grossman School of Medicine, completed his residency and chief residency at the University of Rochester, followed by dual fellowships in hematology and medical oncology at the Johns Hopkins University School of Medicine. After completing his fellowships, Dr. Gladstone became further involved in clinical research, immunotherapy and in blood and bone marrow transplantation research. He is an associate professor of medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell.

In addition, Dr. Gladstone will partner with Cancer Institute leadership to further advance faculty engagement in clinical research recruitment and catalyze new clinical and translational research initiatives. He will work collaboratively with leadership to improve process and flow within the outpatient R.J. Zuckerberg Cancer Center to support efficiencies, programmatic growth and oversee the future transfer of the bone marrow transplant and leukemia units from North Shore University Hospital in Manhasset to the R.J. Zuckerberg Cancer Hospital at Long Island Jewish Medical Center in New Hyde Park.

With more than 400 physicians, Northwell Health Cancer Institute treats more than 19,000 cancer patients annually, more than any other provider in New York State.

Other Executives In the News

Medical Device News Magazine
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Executives on the Move

Dr. Val Kolesnitchenko brings extensive ophthalmology experience in clinical practice and industry to new therapeutics for the aging eye.
These strategic appointments signify a significant milestone for BRIJ Medical as they usher in a new era of post-surgical and trauma incision care with proven technologies that minimize wound complications and scarring.
Dr. Eckhard von Keutz has extensive experience in designing and conducting preclinical/toxicological studies, and toxicological risk assessment and management.
David Kroekel has more than 35 years of experience in medical device, combination product operations, and product development.
Dr. Konstantin Kousoulas, a leading virologist will work to further Rational Vaccines core mission of eradicating the world of the herpes simplex virus. "Dr. Kousoulas...

By using this website you agree to accept Medical Device News Magazine Privacy Policy